Regeneron Strikes Deal With Genentech To Market Eylea

Law360, New York (January 3, 2012, 2:19 PM EST) -- Regeneron Pharmaceuticals Inc. has partially settled its patent litigation in New York against Genentech Inc., securing a licensing agreement in order to market Eylea, a treatment for macular degeneration, the company announced Tuesday.

Under the nonexclusive licensing agreement, Regeneron agreed to pay Roche Group unit Genentech $60 million until May 2016 if sales of Regeneron’s Eylea reached $400 million. Additionally, Regeneron said it had agreed to pay almost 5 percent in royalties if U.S. sales of Eylea were $400 million to $3 billion.

If U.S. sales...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.